EP4125920A4 - Methods and compositions for treatment of covid-19 - Google Patents

Methods and compositions for treatment of covid-19

Info

Publication number
EP4125920A4
EP4125920A4 EP21781244.5A EP21781244A EP4125920A4 EP 4125920 A4 EP4125920 A4 EP 4125920A4 EP 21781244 A EP21781244 A EP 21781244A EP 4125920 A4 EP4125920 A4 EP 4125920A4
Authority
EP
European Patent Office
Prior art keywords
covid
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21781244.5A
Other languages
German (de)
French (fr)
Other versions
EP4125920A1 (en
Inventor
Rafi Israel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esrail Medical Corp
Esrail Medical Corp
Original Assignee
Esrail Medical Corp
Esrail Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esrail Medical Corp, Esrail Medical Corp filed Critical Esrail Medical Corp
Publication of EP4125920A1 publication Critical patent/EP4125920A1/en
Publication of EP4125920A4 publication Critical patent/EP4125920A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21781244.5A 2020-03-28 2021-03-29 Methods and compositions for treatment of covid-19 Pending EP4125920A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001284P 2020-03-28 2020-03-28
PCT/US2021/024745 WO2021202429A1 (en) 2020-03-28 2021-03-29 Methods and compositions for treatment of covid-19

Publications (2)

Publication Number Publication Date
EP4125920A1 EP4125920A1 (en) 2023-02-08
EP4125920A4 true EP4125920A4 (en) 2024-04-10

Family

ID=77929760

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21781244.5A Pending EP4125920A4 (en) 2020-03-28 2021-03-29 Methods and compositions for treatment of covid-19

Country Status (3)

Country Link
US (2) US11826379B2 (en)
EP (1) EP4125920A4 (en)
WO (1) WO2021202429A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL286573B (en) * 2010-09-29 2022-08-01 Pulmatrix Operating Co Inc Monovalent metal cation dry powders for inhalation
US20140328797A1 (en) * 2013-05-01 2014-11-06 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
US10603299B2 (en) * 2016-06-02 2020-03-31 Steven Baranowitz Prevention and treatment of viral infections
BR112020025212A2 (en) * 2018-07-05 2021-03-09 Hangzhou Dac Biotech Co., Ltd CROSSADY CONNECTED PIRROLOBENZODIAZEPINE DYMER DERIVED, CONJUGATED WITH A CROSSADY PIRROLOBENZODIAZEPINE DYMER DERIVED CONNECTED TO A CELL-CONNECTING MOLECULE, L1 AND L2, CELL-CUTTING LEMON, CHEMOTHERAPEUTIC AND SYNERGIC AGENTS
CN111748571B (en) * 2019-10-11 2022-05-03 浙江禾霖生物科技有限公司 Method for engineering bacillus subtilis into multifunctional stable platform for producing nano antibody

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELFIKY ABDO A: "Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study", LIFE SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 253, 25 March 2020 (2020-03-25), XP086155203, ISSN: 0024-3205, [retrieved on 20200325], DOI: 10.1016/J.LFS.2020.117592 *
MANLI WANG ET AL: "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", CELL RESEARCH, 4 February 2020 (2020-02-04), Singapore, XP055672526, ISSN: 1001-0602, DOI: 10.1038/s41422-020-0282-0 *
See also references of WO2021202429A1 *
TSAI LI-KAI ET AL: "Neuromuscular Disorders in Severe Acute Respiratory Syndrome", ARCHIVES OF NEUROLOGY, vol. 61, no. 11, 1 November 2004 (2004-11-01), US, pages 1669, XP093134219, ISSN: 0003-9942, Retrieved from the Internet <URL:https://dx.doi.org/10.1001/archneur.61.11.1669> DOI: 10.1001/archneur.61.11.1669 *
XIE ET AL: "Mutiple organ damage caused by a novel tick-borne Bunyavirus: A case report", JOURNAL OF VECTOR BORNE DISEASES, 1 October 2013 (2013-10-01), pages 314 - 317, XP093134231, Retrieved from the Internet <URL:https://journals.lww.com/jvbd/Fulltext/2013/50040/Mutiple_organ_damage_caused_by_a_novel_tick_borne.13.aspx> [retrieved on 20240222] *

Also Published As

Publication number Publication date
US20230022162A1 (en) 2023-01-26
EP4125920A1 (en) 2023-02-08
US20240091246A1 (en) 2024-03-21
WO2021202429A1 (en) 2021-10-07
US11826379B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
IL300067A (en) Compositions and methods for treatment of cancers
EP4136254A4 (en) Ace2-targeted compositions and methods for treating covid-19
IL308221A (en) Compositions and methods for the treatment of depression
EP4110369A4 (en) Methods of treatment and related compositions
IL289251A (en) Methods and compositions for treatment of pancreatic cancer
EP4138852A4 (en) Compositions and methods for the treatment of pain
EP4100029A4 (en) Compositions and methods of use thereof for treatment of mastitis
IL278978A (en) Compositions and methods for treatment of psoriasis
GB201913122D0 (en) Compositions and methods for treatment of cholangiocarcinoma
EP4142740A4 (en) Compositions and methods of use thereof
IL288415A (en) Compositions and methods for treatment of hemochromatosis
EP4099997A4 (en) Methods and compositions for treatment of diseases
EP4114864A4 (en) Compositions and methods for treatment of cancer
IL287538A (en) Compositions and methods for treatment of cancer
GB202319843D0 (en) CAS13-based compositions and methods of use thereof
EP4114411A4 (en) Compositions and methods for the treatment of pancreatic cancer
EP4125920A4 (en) Methods and compositions for treatment of covid-19
GB201913121D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB201913124D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB202000248D0 (en) Compositions and methods of treatment
GB201810923D0 (en) Compositions and method of treatment
GB202318443D0 (en) Compositions and methods of treatment
GB202218196D0 (en) Compositions and methods of treatment
IL309952A (en) Compositions and methods for treatment of melanoma
GB202107966D0 (en) Composition and method of treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221028

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031560000

Ipc: A61K0031705600

A4 Supplementary search report drawn up and despatched

Effective date: 20240313

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/21 20060101ALI20240306BHEP

Ipc: A61K 31/575 20060101ALI20240306BHEP

Ipc: A61K 31/56 20060101ALI20240306BHEP

Ipc: A61P 31/14 20060101ALI20240306BHEP

Ipc: A61K 31/65 20060101ALI20240306BHEP

Ipc: A61K 31/7056 20060101AFI20240306BHEP